<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829565</url>
  </required_header>
  <id_info>
    <org_study_id>19-AOI-11</org_study_id>
    <nct_id>NCT04829565</nct_id>
  </id_info>
  <brief_title>Assessment of Pain After Intra-articular Botulinum Toxin Injections in Carpometacarpal Osteoarthritis of the Thumb</brief_title>
  <official_title>Assessment of Pain After Intra-articular Botulinum Toxin Injections in Carpometacarpal Osteoarthritis of the Thumb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Only 4 randomized controlled clinical trials have been published to date to assess the&#xD;
      short-term effectiveness of intra-articular Botulinum Toxin injection on pain, function and&#xD;
      quality of life in patients suffering from chronic knee pain related or not to knee&#xD;
      osteoarthritis and also in the context of ankle osteoarthritis. The analgesic properties and&#xD;
      the reported safety make intra-articular Botulinum toxin a strong candidate in the treatment&#xD;
      of symptomatic manifestations of osteoarthritis disease and more particularly in certain&#xD;
      locations such as the trapezo-metacarpal joint. Investigators hypothesize that injection of&#xD;
      intra-articular Botulinum toxin into the trapezo-metacarpal joint will be of benefit in&#xD;
      reducing pain and improving function in patients with rhizarthrosis. Investigators will begin&#xD;
      a monocentric randomized controlled trial comparing intra-articular injections of Botulinum&#xD;
      toxin and placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 29, 2021</start_date>
  <completion_date type="Anticipated">June 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale at 3 months</measure>
    <time_frame>3 months after the injection</time_frame>
    <description>Evolution of the initial pain by Visual Analogue Scale compared to that measured at 3 months after the injection. Score from 0 to 10. 0 corresponds to the absence of pain and 10 to the maximum imaginable pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dreiser test evaluation</measure>
    <time_frame>3 months after the injection</time_frame>
    <description>Dreiser test evaluation (functional index evaluation) at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Collecting adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale at 8 weeks</measure>
    <time_frame>8 weeks after the injection</time_frame>
    <description>Evaluation of pain by Visual Analogue Scale at 8 weeks. Score from 0 to 10. 0 corresponds to the absence of pain and 10 to the maximum imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intake of analgesic and anti-inflammatory drugs during the study period</measure>
    <time_frame>from the injection at Month 0 to the evaluation at Month 3, assessed up to 3 months</time_frame>
    <description>Evaluate the intake of analgesic and anti-inflammatory drugs during the study period: collection of the consumption of analgesics and non-steroidal anti-inflammatory drugs in the patient's diary (international non-proprietary name, dosage, date and time) from the injection at Month 0 to the evaluation at Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep quality</measure>
    <time_frame>3 months after the injection</time_frame>
    <description>sleep quality (Spiegel sleep questionnaire ) at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 months after the injection</time_frame>
    <description>quality of life (SF-36 scale -) at 3 months. a score for each dimension of the SF-36 was calculated, ranging from 0 to 100. A low score reflects a perception of poor health, loss of function, and presence of pain. A high score reflects a perception of good health, absence of functional deficit and pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>botulinum toxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 IU of botulinum toxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 IU of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin</intervention_name>
    <description>echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU</description>
    <arm_group_label>botulinum toxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient &gt;18 years old&#xD;
&#xD;
          -  Patient with rhizarthrosis objectified by interrogation, radiography with at least 2&#xD;
             of the following criteria: osteophyte, joint space narrowing, subchondral sclerosis or&#xD;
             geode&#xD;
&#xD;
          -  Patient who has had an X-ray of the wrist (face, profile and Kapandji incidence) to&#xD;
             estimate the severity of the rhizarthrosis.&#xD;
&#xD;
          -  Patient with signed informed consent.&#xD;
&#xD;
          -  Visual analog scale (VAS) of pain &gt; 4&#xD;
&#xD;
          -  Failure of well-conducted drug treatments with level 1 and 2 analgesics,&#xD;
             anti-inflammatory drugs and orthotic devices&#xD;
&#xD;
          -  Patients must have stopped all corticosteroid or non-steroidal anti-inflammatory drugs&#xD;
             therapy within the last 48 hours.&#xD;
&#xD;
          -  Patient affiliated with a Social Security plan&#xD;
&#xD;
          -  Patient who can understand the study instructions&#xD;
&#xD;
          -  Patient on effective contraception for more than one month according to the marketing&#xD;
             authorization (Pill, intrauterine device, vaginal ring, contraceptive skin patch,&#xD;
             hormonal subcutaneous implant)&#xD;
&#xD;
          -  Infertile patients in connection with surgery (tubal ligation, oophorectomy,&#xD;
             adnexectomy, hysterectomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of surgery of the thumb column&#xD;
&#xD;
          -  Patient who has received an intra-articular trapezoidal metacarpal injection of&#xD;
             corticoids, botulinum toxin or hyaluronic acid or other product within the last 6&#xD;
             months.&#xD;
&#xD;
          -  Patient who has received a Botulinum toxin injection at any site within the last 3&#xD;
             months&#xD;
&#xD;
          -  Myasthenia or Lambert-Eaton disease, neuromuscular dysfunction, hypersensitivity to&#xD;
             incobotulinumtoxin A, severe respiratory disorder or severe swallowing disorder&#xD;
&#xD;
          -  Patients with hypersensitivity to botulinum toxin or to any of the excipients (human&#xD;
             albumin sucrose)&#xD;
&#xD;
          -  Patient with an infection or inflammation at the injection site concerned&#xD;
&#xD;
          -  Pregnant or breastfeeding women (a urine pregnancy test will be performed)&#xD;
&#xD;
          -  Patients with chronic inflammatory joint disease or microcrystalline pathology&#xD;
&#xD;
          -  Current participation or less than 30 days of participation in a clinical drug trial&#xD;
&#xD;
          -  Any medical or psychiatric condition that could prevent the proper understanding and&#xD;
             conduct of the treatment and study (adult under guardianship)&#xD;
&#xD;
          -  Patient who wishes to discontinue contraception during the study&#xD;
&#xD;
          -  Patients at high risk of bleeding complications from the intra-articular injection&#xD;
             (hemophilia, anticoagulant treatment, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Blanc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Blanc</last_name>
    <phone>0492039655</phone>
    <phone_ext>+33</phone_ext>
    <email>blanc.p@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Roux</last_name>
    <phone>0492035779</phone>
    <phone_ext>+33</phone_ext>
    <email>roux.c@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <state>Paca</state>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Blanc</last_name>
      <phone>0492039655</phone>
      <phone_ext>+33</phone_ext>
      <email>blanc.p@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christian Roux</last_name>
      <phone>0492035779</phone>
      <phone_ext>+33</phone_ext>
      <email>roux.c@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Stéphane Glenet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

